Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Resource use in patients with psoriasis after the introduction of biologics in Sweden
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Dermatologi och venereologi. The Swedish Institute for Health Economics, Lund.
Department of Clinical Sciences, Skåne University Hospital, Clinical Research, Lund University, Malmö, Sweden.
Institute for Economic Research, School of Economics, Lund University, Lund, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Dermatologi och venereologi.ORCID-id: 0000-0002-3858-8474
2015 (engelsk)Inngår i: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 95, nr 2, s. 156-161Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. To estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including long-term sick leave and disability pension, was estimated as the difference compared to matched controls from the general population. Total direct cost (in SEK 2009 price level) increased from SEK 348 million in 2006 to SEK 459 million in 2009, whereas the total productivity loss decreased from SEK 1,646 to 1,618 million between 2006 and 2009. Although direct costs, especially for biologic agents, have increased for patients with psoriasis over time, this study indicates that costs related to productivity loss are still more substantial.

sted, utgiver, år, opplag, sider
2015. Vol. 95, nr 2, s. 156-161
Emneord [en]
Psoriasis, Cost of illness, Productivity loss, Biologics
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-81898DOI: 10.2340/00015555-1895ISI: 000349270900007PubMedID: 24819980Scopus ID: 2-s2.0-84928235405OAI: oai:DiVA.org:umu-81898DiVA, id: diva2:658763
Tilgjengelig fra: 2013-10-22 Laget: 2013-10-22 Sist oppdatert: 2023-03-23bibliografisk kontrollert
Inngår i avhandling
1. Effectiveness and costs of new medical technologies: register-based research in psoriasis
Åpne denne publikasjonen i ny fane eller vindu >>Effectiveness and costs of new medical technologies: register-based research in psoriasis
2013 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Psoriasis is a chronic, immunological and systemic disease with an estimated prevalence of about 2-3 percent. Psoriasis is associated with the joint disease psoriasis arthropathy. There are several treatments options available for psoriasis and patients with moderate to severe psoriasis generally need systemic agents. In 2004 biologics were introduced for patients with moderate to severe psoriasis in Sweden.

The overall objective of this thesis was to assess the relationship between Health Related Quality of Life (HRQOL) and clinical outcome measures in psoriasis patients, to analyse the effectiveness of biologics in psoriasis in everyday clinical practice and to explore how costs of the psoriasis population changed after the introduction of biologics in Sweden.

Methods: Research was based on national administrative registers and PsoReg, the Swedish registry for systemic treatment of psoriasis. In a cross-sectional study (paper I) the three outcome measures: the generic HRQOL measure EQ-5D, the dermatology specific HRQOL measure the Dermatology Life Quality Index (DLQI) and the clinical measure of skin involvement, Psoriasis Area and Severity Index (PASI), were analysed by demographic characteristics. The generic EQ-5D among psoriasis patients was compared to previously published values for the general population in Sweden. Relationships between measures were examined with correlation tests and regression analysis. A longitudinal study included patients registered in PsoReg who switched to a biologic agent for the first time during registration (paper II). The three outcomes EQ-5D, DLQI, and PASI were analysed before and after switch in the overall patient group and in subgroups. The relative effectiveness of continuing with the standard care of conventional treatment compared to switching from standard care to biologics was analysed in patients with moderate to severe psoriasis (paper III). Patients in PsoReg were matched with propensity scores and average treatment effects were estimated. The estimated outcomes were the change of EQ-5D, DLQI, and PASI. Patients were identified in national registers at the National Board of Health and Welfare when analysing costs; either by a registration of a psoriasis diagnosis in the national patients register and/or by a registration in the prescribed drugs register of a topical treatment with calcipotriol, a substance which has the indication psoriasis only (paper IV). Direct costs included patients’ visits in specialist health care and prescribed drugs used for psoriasis treatment, retrieved from the national patients register and the prescribed drugs register, respectively. Indirect costs included productivity loss in terms of sick leave and disability pension, which estimated as excess costs compared to controls. Controls were selected from the normal population and matched on sex, age and municipality. Productivity loss was estimated based on data from the Longitudinal integration database for health insurance and labour market studies at Statistics Sweden.

Results: Patients with moderate to severe psoriasis had significantly lower HRQOL in EQ-5D than the general population (paper I). Women rated their HRQOL lower than men, even though men had more severe clinical skin involvement than women. (paper I). The generic measure EQ-5D and the dermatology-specific DLQI had moderate correlations whereas EQ-5D had low correlation with the clinical measure PASI (paper I). Patients who switched to a biologic agent during registration in PsoReg had significant improvements in all outcomes (paper II). Patients who fulfilled the criteria for moderate to severe psoriasis had the highest benefits of the biologic agents (paper II). The matched conventionally and biologically treated patients with moderate to severe psoriasis were essentially equal in important observable variables (paper III). The subgroup of patients not responding to conventional treatment had high potential benefits of biologic agents (paper III). Individuals with psoriasis had sick leave and disability pension to a larger extent than their matched controls (paper IV). Direct costs increased, whereas the indirect costs of productivity loss decreased between 2006 and 2009 (paper IV).

Conclusion: Psoriasis is associated both with direct costs and indirect costs, and it has a negative impact on patients’ HRQOL. When evaluating psoriasis treatments and making decisions about treatment guidelines, both generic, dermatology-specific HRQOL measures, and clinical measures are necessary; as they answer to different needs. Although dependent on data quality, generalisability, and current pricing, results suggest that conventional treatments are suitable as first line and biologic agents as second line treatment. Results indicate that the different types of systemic treatments are not allocated optimally among patients with psoriasis in Swedish clinical practice.

sted, utgiver, år, opplag, sider
Umeå: Umeå universitet, 2013. s. 54
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1606
Emneord
Psoriasis, registers, EQ-5D, DLQI, PASI, biologics
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-81899 (URN)978-91-7459-740-0 (ISBN)
Disputas
2013-11-14, Bergasalen hörsal, Norrlands Universitetsjukhus, Umeå, 10:00 (svensk)
Opponent
Veileder
Tilgjengelig fra: 2013-10-23 Laget: 2013-10-22 Sist oppdatert: 2018-06-08bibliografisk kontrollert

Open Access i DiVA

fulltext(404 kB)315 nedlastinger
Filinformasjon
Fil FULLTEXT02.pdfFilstørrelse 404 kBChecksum SHA-512
851a046c143bc79720330a1c24011bb436ffc4db85d7be1ea5d51be21f77e4c1b729df240a8f97e3cf44d6ae7857cca460240994defbda86ae0a89731ee2a709
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Norlin, Jenny M.Schmitt-Egenolf, Marcus

Søk i DiVA

Av forfatter/redaktør
Norlin, Jenny M.Schmitt-Egenolf, Marcus
Av organisasjonen
I samme tidsskrift
Acta Dermato-Venereologica

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 331 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 718 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf